We are excited to congratulate one of our 2025–2026 Biolocity cohort teams, OnCuRNA, on the publication of their recent paper in Nature Communications!

The study, “Tumor-agnostic drug delivery with dynamic nanohydrogels,” describes the development of a novel self-agglomerating nanohydrogel (SANG) platform designed to overcome one of the biggest challenges in oncology: safely and effectively delivering RNA-based therapeutics to solid tumors. Unlike traditional delivery systems, this approach does not rely on tumor-specific targeting ligands, yet still demonstrates strong and selective accumulation in both primary and metastatic tumors across multiple cancer models and species.

The work shows that these SANGs can successfully deliver RNA interference (RNAi) payloads to suppress oncogene expression, sensitize drug-resistant tumors, and do so with minimal toxicity—highlighting their potential as a versatile, tumor-agnostic delivery technology for next-generation cancer therapeutics.

This publication represents an exciting milestone for the team and underscores the translational potential of innovations emerging from the Biolocity program. We are proud to support this work as it advances toward future therapeutic development.

Read the full publication here: https://doi.org/10.1038/s41467-025-66788-4